Modern CNS drug discovery : reinventing the treatment of psychiatric and neurological disorders / Rudy Schreiber, editor.
Schreiber, Rudy, editor.
2021
RM315
Available Online

Linked e-resources

Linked Resource
Online Access
Concurrent users
Unlimited
Authorized users
Authorized users
Document Delivery Supplied
Can lend chapters, not whole ebooks

Details

Title
Modern CNS drug discovery : reinventing the treatment of psychiatric and neurological disorders / Rudy Schreiber, editor.
ISBN
9783030623517 (electronic bk.)
3030623513 (electronic bk.)
3030623505
9783030623500
DOI
https://doi.org/10.1007/978-3-030-62351-7
Publication Details
Cham : Springer, 2021.
Language
English
Description
1 online resource
Item Number
10.1007/978-3-030-62351-7 doi
Call Number
RM315
Dewey Decimal Classification
615.7/8
Summary
This textbook provides a comprehensive overview of the currently used concepts, approaches and technologies in the discovery and development of new treatments for the full spectrum of disorders of the central nervous system. It guides the reader through all essential steps, from finding an innovative idea, to the registration of a new drug. Divided into four sections, the book starts by presenting a broad perspective on current approaches in central nervous system (CNS) drug discovery. The second section addresses the generation of ideas for the identification of targets and novel treatment strategies; covers core functions in early discovery, and provides an example of a novel treatment paradigm: brain stimulation. The third section highlights strategies and technologies in translational CNS drug discovery. In an effort to bridge the gap between discovery and clinical development, it also covers brain imaging, EEG and cognitive testing approaches. The fourth section extensively discusses the clinical phase of drug development, covering the basics of early clinical testing for psychopharmacological drugs. The book's final chapter addresses the registration for newly developed drugs. Written by experts from academia and industry, the book covers important basics and best practices, as well as recent developments in drug discovery. Offering in-depth insights into the world of drug development, it represents essential reading for early researchers who want to prepare for a career in drug discovery in academia or industry.
Access Note
Access limited to authorized users.
Source of Description
Online resource; title from PDF title page (SpringerLink, viewed June 30, 2021).
Added Author
Schreiber, Rudy, editor.
Available in Other Form
Modern CNS drug discovery.
Linked Resources
Online Access
Record Appears in
Online Resources > Ebooks
All Resources
PART I
Introduction
Innovator, Entrepreneur, Leader: The Tripartite Drug Discovery Neuroscientist
PART II
Innovation in the Discovery of Novel Therapeutic Approaches
Drug Discovery in CNS: Finding a Target for What?
Neurogenomics with Application to Schizophrenia and Other Major Neuropsychiatric Diseases with Complex Heredity
Epigenetics in Drug Discovery: Achievements and Challenges
Conventional Behavioral Models and Readouts in Drug Discovery: The Importance of Improving Translation
Safety and Drug Metabolism: Toward NCE and First in Human
The Various Forms of Non-invasive Brain Stimulation and Their Clinical Relevance
Is Non-invasive Brain Stimulation the Low-Hanging Fruit?
PART III
Translational Medicine and Technology
Electrophysiology: From Molecule to Cognition, from Animal to Human
MRI in CNS Drug Development
Positron Emission Tomography in Drug Development
Application of Cognitive Test Outcomes for Clinical Drug Development
Exciting Research in the Field of Sexual Psychopharmacology: Treating Patients with Inside Information
A Paradigm Shift from DSM-5 to Research Domain Criteria: Application to Translational CNS Drug Development
PART IV
Clinical Development and Regulatory Approval
The Special Challenges of Developing CNS Drugs
Phase 1 Clinical Trials in Psychopharmacology
Early Development of Erenumab for Migraine Prophylaxis
Microdosing Psychedelics as a Promising New Pharmacotherapeutic
Partnering with the FDA.

Browse Subjects

Show more subjects...

Statistics

from
to
Export